Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1771735
PUBLISHER: Grand View Research | PRODUCT CODE: 1771735
U.S. Active Pharmaceutical Ingredients CDMO Market Size, Share & Trends Analysis Report By Product (Traditional API, HP-API, ADC), By Synthesis, By Drug, By Workflow, By Application, And Segment Forecasts, 2025 - 2030
PUBLISHED:
PAGES: 80 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Market Size & Trends:
The U.S. active pharmaceutical ingredients CDMO market was valued at USD 25.28 billion in 2024 and is projected to reach USD 33.86 billion by 2030, growing at a CAGR of 5.1% from 2025 to 2030. This growth is driven by rising demand for advanced pharmaceutical manufacturing services to support the development of innovative drugs and therapies. In addition, increasing investments in biologics and high-potency APIs drive market expansion. The growing prevalence of chronic diseases and the need for efficient, scalable production solutions also contribute to the market's momentum.
Key drivers supporting this market growth include technological advancements in process chemistry and manufacturing automation, which improve yield, reduce waste, and enhance product quality. Regulatory support encouraging outsourcing to specialized CDMOs is vital, as these organizations help ensure compliance with stringent FDA and international standards. The increasing focus on personalized medicine and novel therapies drives demand for small-batch, complex API manufacturing, areas where CDMOs excel due to their flexibility and expertise. Growing collaborations between pharmaceutical firms and CDMOs also foster innovation and accelerate time-to-market, enabling companies to meet better evolving patient better needs.
The market presents significant opportunities, especially in developing biologics, gene therapies, and cell therapies requiring highly specialized API manufacturing. The trend toward continuous manufacturing and flow chemistry offers avenues for CDMOs to improve efficiency and scalability while reducing costs and environmental impact.
U.S. Active Pharmaceutical Ingredients CDMO Market Report Segmentation
This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. active pharmaceutical ingredients CDMO market report based on product, synthesis, drug, workflow, and application.
- Product Outlook (Revenue, USD Million, 2018 - 2030)
- Traditional Active Pharmaceutical Ingredient
- Highly Potent Active Pharmaceutical Ingredient
- Antibody Drug Conjugate (ADC)
- Other
- Synthesis Outlook (Revenue, USD Million, 2018 - 2030)
- Synthetic
- Biotech
- Drug Outlook (Revenue, USD Million, 2018 - 2030)
- Innovative
- Generic
- Workflow Outlook (Revenue, USD Million, 2018 - 2030)
- Clinical
- Commercial
- Application Outlook (Revenue, USD Million, 2018 - 2030)
- Oncology
- Hormonal
- Glaucoma
- Cardiovascular disease
- Diabetes
- Others
Product Code: GVR-4-68040-629-9
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definition
- 1.3. Information Procurement
- 1.3.1. Purchased Database
- 1.3.2. GVR's Internal Database
- 1.3.3. Secondary Sources and Third-Party Perspectives
- 1.3.4. Primary Research
- 1.4. Information Analysis
- 1.4.1. Data Analysis Models
- 1.5. Market Formulation and Data Visualization
- 1.6. Data Validation and Publishing
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Active Pharmaceutical Ingredients CDMO Market Variables, Trends and Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.2.3. Industry Challenge
- 3.3. Industry Analysis Tools
- 3.3.1. PORTER's Analysis
- 3.3.1.1. Bargaining power of the suppliers
- 3.3.1.2. Bargaining power of the buyers
- 3.3.1.3. Threats of substitution
- 3.3.1.4. Threats from new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Economic and social landscape
- 3.3.2.3. Technological landscape
- 3.3.1. PORTER's Analysis
Chapter 4. U.S. Active Pharmaceutical Ingredients CDMO Market: Product Estimates and Trend Analysis
- 4.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Product: Key Takeaways
- 4.2. Product Movement Analysis and Market Share, 2024 and 2030
- 4.3. Market Estimates and Forecasts, By Product, 2018 - 2030 (USD Million)
- 4.3.1. Traditional Active Pharmaceutical Ingredient
- 4.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.3.2. Highly Potent Active Pharmaceutical Ingredient
- 4.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.3.3. Antibody Drug Conjugate (ADC)
- 4.3.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.3.4. Other
- 4.3.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.3.1. Traditional Active Pharmaceutical Ingredient
Chapter 5. U.S. Active Pharmaceutical Ingredients CDMO Market: Synthesis Estimates and Trend Analysis
- 5.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Synthesis: Key Takeaways
- 5.2. Synthesis Movement Analysis and Market Share, 2024 and 2030
- 5.3. Market Estimates and Forecasts, By Synthesis, 2018 - 2030 (USD Million)
- 5.3.1. Synthetic
- 5.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.3.2. Biotech
- 5.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.3.1. Synthetic
Chapter 6. U.S. Active Pharmaceutical Ingredients CDMO Market: Drug Estimates and Trend Analysis
- 6.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Drug: Key Takeaways
- 6.2. Drug Movement Analysis and Market Share, 2024 and 2030
- 6.3. Market Estimates and Forecasts, By Drug, 2018 - 2030 (USD Million)
- 6.3.1. Innovative
- 6.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.2. Generic
- 6.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.1. Innovative
Chapter 7. U.S. Active Pharmaceutical Ingredients CDMO Market: Workflow Estimates and Trend Analysis
- 7.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Workflow: Key Takeaways
- 7.2. Workflow Movement Analysis and Market Share, 2024 and 2030
- 7.3. Market Estimates and Forecasts, By Workflow, 2018 - 2030 (USD Million)
- 7.3.1. Clinical
- 7.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2. Commercial
- 7.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.1. Clinical
Chapter 8. U.S. Active Pharmaceutical Ingredients CDMO Market: Application Estimates and Trend Analysis
- 8.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Application: Key Takeaways
- 8.2. Application Movement Analysis and Market Share, 2024 and 2030
- 8.3. Market Estimates and Forecasts, By Application, 2018 - 2030 (USD Million)
- 8.3.1. Oncology
- 8.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.2. Hormonal
- 8.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.3. Glaucoma
- 8.3.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.4. Cardiovascular disease
- 8.3.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.5. Diabetes
- 8.3.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.6. Others
- 8.3.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.1. Oncology
Chapter 9. Competitive Landscape
- 9.1. Company Categorization
- 9.2. Company Market Positioning
- 9.3. Company Heat Map Analysis
- 9.4. Company Profiles/Listing
- 9.4.1. Thermo Fisher Scientific Inc.
- 9.4.1.1. Company Overview
- 9.4.1.2. Financial Performance
- 9.4.1.3. Product Portfolio
- 9.4.1.4. Recent Developments/ Strategic Initiatives
- 9.4.2. Novo Group (Catalent, Inc.)
- 9.4.2.1. Company Overview
- 9.4.2.2. Financial Performance
- 9.4.2.3. Product Portfolio
- 9.4.2.4. Recent Developments/ Strategic Initiatives
- 9.4.3. Cambrex Corporation
- 9.4.3.1. Company Overview
- 9.4.3.2. Financial Performance
- 9.4.3.3. Product Portfolio
- 9.4.3.4. Recent Developments/ Strategic Initiatives
- 9.4.4. Piramal Pharma Limited
- 9.4.4.1. Company Overview
- 9.4.4.2. Financial Performance
- 9.4.4.3. Product Portfolio
- 9.4.4.4. Recent Developments/ Strategic Initiatives
- 9.4.5. Corden Pharma
- 9.4.5.1. Company Overview
- 9.4.5.2. Financial Performance
- 9.4.5.3. Product Portfolio
- 9.4.5.4. Recent Developments/ Strategic Initiatives
- 9.4.6. Siegfried Holding AG
- 9.4.6.1. Company Overview
- 9.4.6.2. Financial Performance
- 9.4.6.3. Product Portfolio
- 9.4.6.4. Recent Developments/ Strategic Initiatives
- 9.4.7. Seqens North America
- 9.4.7.1. Company Overview
- 9.4.7.2. Financial Performance
- 9.4.7.3. Product Portfolio
- 9.4.7.4. Recent Developments/ Strategic Initiatives
- 9.4.8. SK pharmteco Inc.
- 9.4.8.1. Company Overview
- 9.4.8.2. Financial Performance
- 9.4.8.3. Product Portfolio
- 9.4.8.4. Recent Developments/ Strategic Initiatives
- 9.4.9. Noramco.
- 9.4.9.1. Company Overview
- 9.4.9.2. Financial Performance
- 9.4.9.3. Product Portfolio
- 9.4.9.4. Recent Developments/ Strategic Initiatives
- 9.4.10. BSP Pharmaceuticals
- 9.4.10.1. Company Overview
- 9.4.10.2. Financial Performance
- 9.4.10.3. Product Portfolio
- 9.4.10.4. Recent Developments/ Strategic Initiatives
- 9.4.1. Thermo Fisher Scientific Inc.
Product Code: GVR-4-68040-629-9
List of Tables
- Table 1 List of abbreviations
- Table 2 U.S active pharmaceutical ingredients CDMO market: key market driver analysis
- Table 3 U.S active pharmaceutical ingredients CDMO market: Key market restraint analysis
- Table 4 U.S active pharmaceutical ingredients CDMO market estimates and forecast, by product (USD Million)
- Table 5 U.S active pharmaceutical ingredients CDMO market estimates and forecast, by synthesis (USD Million)
- Table 6 U.S active pharmaceutical ingredients CDMO market estimates and forecast, by drug (USD Million)
- Table 7 U.S active pharmaceutical ingredients CDMO market estimates and forecast, by workflow (USD Million)
- Table 8 U.S active pharmaceutical ingredients CDMO market estimates and forecast, by application (USD Million)
- Table 9 Recent developments and impact analysis by key market participants
- Table 10 Company heat map analysis, 2024
- Table 11 Companies implementing key strategies
List of Figures
- Fig. 1 U.S active pharmaceutical ingredients CDMO market segmentation
- Fig. 2 Market research process
- Fig. 3 Information procurement
- Fig. 4 Primary research pattern
- Fig. 5 Market research approaches
- Fig. 6 Value chain-based sizing and forecasting
- Fig. 7 Parent market analysis
- Fig. 8 Market formulation and validation
- Fig. 9 U.S active pharmaceutical ingredients CDMO market snapshot
- Fig. 10 U.S active pharmaceutical ingredients CDMO market segment snapshot
- Fig. 11 U.S active pharmaceutical ingredients CDMO market competitive landscape snapshot
- Fig. 12 Market research process
- Fig. 13 Market driver relevance analysis (Current and future impact)
- Fig. 14 Market restraint relevance analysis (Current and future impact)
- Fig. 15 U.S active pharmaceutical ingredients CDMO market: Product outlook key takeaways (USD Million)
- Fig. 16 U.S active pharmaceutical ingredients CDMO market: Product movement analysis 2024 & 2030 (USD Million)
- Fig. 17 Traditional Active Pharmaceutical Ingredient market estimates & forecasts, 2018 - 2030 (USD Million)
- Fig. 18 Highly Potent Active Pharmaceutical Ingredient market estimates & forecasts, 2018 - 2030 (USD Million)
- Fig. 19 Antibody Drug Conjugate (ADC)s market estimates & forecasts, 2018 - 2030 (USD Million)
- Fig. 20 Others market estimates & forecasts, 2018 - 2030 (USD Million)
- Fig. 21 U.S active pharmaceutical ingredients CDMO market: Synthesis outlook key takeaways (USD Million)
- Fig. 22 U.S active pharmaceutical ingredients CDMO market: Synthesis movement analysis 2024 & 2030 (USD Million)
- Fig. 23 Synthetic market estimates & forecasts, 2018 - 2030 (USD Million)
- Fig. 24 Biotech market estimates & forecasts, 2018 - 2030 (USD Million)
- Fig. 25 U.S active pharmaceutical ingredients CDMO market: Drug outlook key takeaways (USD Million)
- Fig. 26 U.S active pharmaceutical ingredients CDMO market: Drug movement analysis 2024 & 2030 (USD Million)
- Fig. 27 Innovative market estimates & forecasts, 2018 - 2030 (USD Million)
- Fig. 28 Generics market estimates & forecasts, 2018 - 2030 (USD Million)
- Fig. 29 Distributed recipient drugs market estimates & forecasts, 2018 - 2030 (USD Million)
- Fig. 30 U.S active pharmaceutical ingredients CDMO market: Workflow outlook key takeaways (USD Million)
- Fig. 31 U.S active pharmaceutical ingredients CDMO market: Workflow movement analysis 2024 & 2030 (USD Million)
- Fig. 32 Clinical market estimates & forecasts, 2018 - 2030 (USD Million)
- Fig. 33 Commercial market estimates & forecasts, 2018 - 2030 (USD Million)
- Fig. 34 U.S active pharmaceutical ingredients CDMO market: Application outlook key takeaways (USD Million)
- Fig. 35 U.S active pharmaceutical ingredients CDMO market: Application movement analysis 2024 & 2030 (USD Million)
- Fig. 36 Oncology market estimates & forecasts, 2018 - 2030 (USD Million)
- Fig. 37 Hormonal market estimates & forecasts, 2018 - 2030 (USD Million)
- Fig. 38 Glaucoma market estimates & forecasts, 2018 - 2030 (USD Million)
- Fig. 39 Cardiovascular disease market estimates & forecasts, 2018 - 2030 (USD Million)
- Fig. 40 Diabetes market estimates & forecasts, 2018 - 2030 (USD Million)
- Fig. 41 Others market estimates & forecasts, 2018 - 2030 (USD Million)
- Fig. 42 Strategy framework
- Fig. 43 Company categorization
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.